Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717064 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03717064 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 18 participants.
The verdict
NCT03717064, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The main purpose of the study is to characterize the interaction between RO7049389 and the cholesterol-lowering drug, pitavastatin, in healthy volunteers. There is no intended clinical benefit to this study. The total duration of the study for each participant is approximately 12 weeks.
Interventions
- DRUG Pitavastatin
- DRUG RO7049389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717064
The ClinicalTrials.gov registry entry for NCT03717064 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pitavastatin is the first listed.
NCT03717064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03717064 about?
NCT03717064 is a clinical study titled "A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers". The main purpose of the study is to characterize the interaction between RO7049389 and the cholesterol-lowering drug, pitavastatin, in healthy volunteers. There is no intended clinical benefit to this study. The total duration of the study for each participant is approximately 12 weeks.
What is the current status of trial NCT03717064?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-11-07. Estimated completion is 2018-12-17.
What interventions are being tested in trial NCT03717064?
The interventions under investigation include: Pitavastatin (DRUG), RO7049389 (DRUG).
Who is sponsoring clinical trial NCT03717064?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.